• About Us
    • About Us
    • Corporate Strategy
    • Our Vision and Values
    • Research & Development
    • Operations
    • Business Development
    • Awards and Grants
  • Announcements
  • Our Team
    • Management Team
    • Scientific Team
    • Scientific Advisory Board
  • Portfolio
    • Our Portfolio
    • Lupuzor™ & Lupus
    • Autoimmunity
    • Anti-infectives
  • Investors
    • Investor Relations
    • AIM Rule 26 Information
    • Regulatory News
    • Market Commentary
    • Share Price
    • Analyst Research
    • Corporate Governance
    • Board of Directors
    • Annual Reports
    • Interviews
    • Professional Advisers
    • Email Alerts
  • Media
    • Events and Conferences
    • Media Room
    • Interviews
    • Scientific Publications
  • Contact Us
Archives
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
September 29, 2020

Share Subscription into Incanthera plc (“Incanthera”)

Read More
September 22, 2020

Repayment of Convertible Security – Lind Global Macro Fund, LP

Read More
September 11, 2020

Update on submission to the FDA for a Special Protocol Assessment (SPA) for the forthcoming international Phase III trial of Lupuzor™ in Lupus Patients

Read More
September 10, 2020

Conversion of Convertible Security – Lind Global Macro Fund, LP

Read More
September 09, 2020

Conversion of Convertible Security – L1 Capital Global Opportunities Master Fund

Read More
September 08, 2020

TR1 – Notification of major interest in shares by Lanstead Capital

Read More
September 08, 2020

Director/PDMR Shareholding/TR-1

Read More
September 07, 2020

Placing to raise £6.5 million – update; related party transaction

Read More
September 03, 2020

Conversion of Convertible Security – L1 Capital Global Opportunities Master Fund

Read More
September 02, 2020

Placing to raise £6.5 million

Read More
September 01, 2020

TR1 – Notification of major interest in shares by Lanstead Capital

Read More
July 27, 2020

Submission to the FDA for a Special Protocol Assessment (SPA) for the forthcoming international Phase III trial of Lupuzor™ in Lupus Patients

Read More
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 17
Aim Rule 26 Contact informationDisclaimerPrivacy PolicySite map

© ImmuPharma PLC 2005-2021 | All rights reserved